# CD30 in T-cell lymphoma

1 EU-approved indication in T-cell lymphoma needs a CD30 result: brentuximab vedotin (2nd line).

## Approved indications

### CD30-positive

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | Monotherapy | 2nd line | Cutaneous T-cell lymphoma only; After at least 1 prior systemic therapy |

## Label wording

- **Brentuximab vedotin** (Adcetris), T-cell lymphoma, 2nd line: “ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/t-cell-lymphoma/cd30